Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,837,383
  • Shares Outstanding, K 86,915
  • Annual Sales, $ 23,680 K
  • Annual Income, $ -318,760 K
  • EBIT $ -306 M
  • EBITDA $ -320 M
  • 60-Month Beta 0.46
  • Price/Sales 16.44
  • Price/Cash Flow N/A
  • Price/Book 16.20

Options Overview Details

View History
  • Implied Volatility 62.66% (-15.39%)
  • Historical Volatility 48.66%
  • IV Percentile 4%
  • IV Rank 13.54%
  • IV High 150.01% on 10/16/25
  • IV Low 48.97% on 02/10/26
  • Expected Move (DTE 7) 1.23 (5.85%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 228
  • Volume Avg (30-Day) 473
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 12,888
  • Open Int (30-Day) 14,786
  • Expected Range 19.83 to 22.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.64
  • Number of Estimates 6
  • High Estimate -0.46
  • Low Estimate -0.82
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +41.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.71 +6.95%
on 01/20/26
22.18 -4.96%
on 01/26/26
+0.61 (+2.98%)
since 01/13/26
3-Month
16.36 +28.85%
on 11/17/25
22.73 -7.26%
on 12/23/25
+4.42 (+26.53%)
since 11/13/25
52-Week
8.58 +145.69%
on 05/15/25
22.73 -7.26%
on 12/23/25
+6.00 (+39.79%)
since 02/13/25

Most Recent Stories

More News
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 21.11 (-0.14%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February...

SNDX : 21.11 (-0.14%)
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively –  – Continued acceleration in demand...

SNDX : 21.11 (-0.14%)
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast...

SNDX : 21.11 (-0.14%)
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 21.11 (-0.14%)
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ®...

SNDX : 21.11 (-0.14%)
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute...

SNDX : 21.11 (-0.14%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December...

SNDX : 21.11 (-0.14%)
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 21.11 (-0.14%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November...

SNDX : 21.11 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 22.54
2nd Resistance Point 22.19
1st Resistance Point 21.66
Last Price 21.11
1st Support Level 20.78
2nd Support Level 20.43
3rd Support Level 19.90

See More

52-Week High 22.73
Last Price 21.11
Fibonacci 61.8% 17.32
Fibonacci 50% 15.65
Fibonacci 38.2% 13.99
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar